A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants

  • Healthy Volunteers
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • United States
Trial Identifier:

NCT02802670 GP29916

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is an open-label, non-randomized study to determine the excretion kinetics and mass balance of GDC-0810, and to determine metabolites present in blood, feces, and urine in healthy participants following a single 300-milligram (mg) oral dose of GDC-0810 containing approximately 100 microcuries of [14C] labeled GDC-0810 using conventional absorption, metabolism, and excretion (AME) methodology. The entire duration of the study is up to approximately 8 weeks.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT02802670,GP29916 Trial Identifier
      [14C]-GDC-0810 Treatments
      Healthy Volunteers Condition

      Eligibility Criteria

      Female Gender
      ≥ 18 Years & ≤ 65 Years Age
      Accepts Healthy Volunteers Healthy Volunteers
      Inclusion Criteria
      • Healthy participants with non-child bearing potential, non-pregnant, non-lactating and either post-menopausal or surgically sterile.
      • Negative pregnancy test result at Screening and at Day -1.
      • Body mass index of 18.5 to 29.9 kilogram per square meter.
      • Healthy condition documented with no clinically significant findings from laboratory evaluations, medical history, 12-lead electrocardiograms, and vital signs.
      Exclusion Criteria
      • Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastric, neurological, or psychiatric disorder.
      • History of significant hypersensitivity or allergy to any drug.
      • Uncontrolled hypothyroidism.
      • History or presence of clinically significant abnormal electrocardiogram.
      • History of venous thrombosis, endometrial disorders, thrombophilic condition, inflammatory bowel disease, chronic diarrhoea, active or latent tuberculosis, and Gilbert's syndrome.
      • Major surgical procedure or significant traumatic injury within 3 months prior to study participation.
      • Participation in more than one other radiolabeled investigational drug study within 12 months prior to Check-in (Day -1).
      • Exposure to significant radiation occuring within 12 months prior to Check-in (Day -1).
      • Any acute or chronic condition that would limit the participant's ability to participate in the clinical study.
      • Failure to satisfy the Investigator of fitness to participate for any other reason.

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now